Chemotherapy for teratoma with malignant transformation Journal Article
| Authors: | Donadio, A.; Motzer, R. J.; Bajorin, D. F.; Kantoff, P. W.; Sheinfeld, J.; Houldsworth, J.; Chaganti, R. S. K.; Bosl, G. J. |
| Article Title: | Chemotherapy for teratoma with malignant transformation |
| Abstract: | Purpose: Teratoma with malignant transformation (MT) is a well-described entity that refers to the MT of a somatic teratomatous component in a germ cell tumor (GCT) to a histology that is identical to a somatic malignancy (eg, rhabdomyosarcoma [RMS]). Surgical resection has been the mainstay of therapy for localized transformed disease because these tumors are thought to be resistant to standard treatment. We report that chemotherapy has a role in selected patients with MT, determined by cell type. Patients and Methods: Chemotherapy was administered to 12 patients with MT of GCT limited to a single cell type (two patients with primitive neuroectodermal tumors, five with undifferentiated RMS, one with anaplastic small-cell tumor, two with adenocarcinoma, and two with leukemia); 10 patients had measurable disease. GCT origin was confirmed by molecular cytogenetics in five patients. Each patient received chemotherapy regimens based on the specific malignant cell observed in the transformed histology. Results: Seven patients with measurable disease achieved a partial response, with the duration of response ranging between 1 month and 7 years. Three of those patients are alive. Three patients did not respond to treatment, and all of those patients died as a result of their disease. Conclusion: Chemotherapy for MT limited to a single cell type may result in major responses and long-term survival in selected patients. Local therapy after chemotherapy is an important component of treatment to achieve maximum response. © 2003 by American Society of Clinical Oncology. |
| Keywords: | adult; cancer chemotherapy; cancer survival; clinical article; controlled study; treatment outcome; treatment response; middle aged; leukemia; cisplatin; doxorubicin; chemotherapy, adjuvant; cytarabine; cancer staging; neoplasm staging; adenocarcinoma; cytogenetics; drug effect; pathology; cell type; cell transformation, neoplastic; cell transformation; adjuvant chemotherapy; carcinoma; testis tumor; testicular neoplasms; teratoma; idarubicin; rhabdomyosarcoma; malignant transformation; germ cell tumor; mediastinum tumor; mediastinal neoplasms; neuroectoderm tumor; neuroectodermal tumors, primitive; small cell carcinoma; carcinoma, small cell; humans; human; male; priority journal; article; mast cell leukemia; leukemia, mast-cell |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 21 |
| Issue: | 23 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2003-12-01 |
| Start Page: | 4285 |
| End Page: | 4291 |
| Language: | English |
| DOI: | 10.1200/jco.2003.01.019 |
| PUBMED: | 14645417 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 12 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work